January 2024 industry update-Reference-Cited by-同舟云学术

January 2024 industry update

Published:2024-05-09 Issue:6 Volume:15 Page:393-398
ISSN:2041-5990
Container-title:Therapeutic Delivery
language:en
Short-container-title:Therapeutic Delivery

Author:

Lim Patrick¹^ORCID,Stilinovic Nebojsa²^ORCID,Mooranian Armin¹³^ORCID,Al-Salami Hani¹⁴^ORCID

Affiliation:

1. The Biotechnology & Drug Development Research Laboratory, Curtin Medical School & Curtin Health Innovation Research Institute, Curtin University, Bentley, 6102, Western Australia, Australia

2. Department of Pharmacology, Toxicology & Clinical Pharmacology, Faculty of Medicine, University of Novi Sad, Hajduk Veljkova 3, Novi Sad, 21000, Serbia

3. School of Pharmacy, University of Otago, Dunedin, 9016, Otago,New Zealand

4. Medical School, University of Western Australia, Crawley, 6009, Western Australia, Australia

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/20415990.2024.2346045

Reference34 articles.

1. Constantino AK. Big pharma is at a crossroads as J&J Merck and others prepare to lose heaps of revenue from blockbuster drugs. 2024. https://www.cnbc.com/2024/01/28/big-pharma-merck-bristol-myers-jj-prepare-to-lose-revenue.html

2. Services CFMM. Medicare Drug Price Negotiation Program: Manufacturer Agreements for Selected Drugs for Initial Price Applicability Year 2026. 2023. https://www.cms.gov/files/document/fact-sheet-manufacturer-agreements-selected-drugs-ipay-2026.pdf

3. Technavio. Topical Corticosteroids Market Analysis North America Europe Asia Rest of World (ROW) – US Canada Saudi Arabia Russia China – Size and Forecast 2023-2027. 2023. https://www.technavio.com/report/topical-corticosteroids-market-analysis?utm_source=prnewswire&utm_medium=prnewswire&utm_campaign=Latest_New_A1_wk05_2024_019_rep&utm_content=IRTNTR75330

4. Cheng M. Novo Nordisk to increase supply of weight-loss drug Wegovy. 2024. https://edition.cnn.com/2024/02/01/health/novo-nordisk-wegovy-weight-loss-drug/index.html

5. Administration FaD. Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss. 2024. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss